Remarkable, groundbreaking progress for cardiometabolic science and medicine!!! #FGF21R #GLP1 #APOC3 #ANGPTL3 #PCSK9 #mAb #siRNA #ASO #CRISPRCas9
Shoutout to ♥️ basic and clinical scientists moving this forward for our patients! @ahascience.bsky.social #AHA25 #PrevCards #Lipidology

#ANGPTL3 it may be time for #ArrowheadTherapeutics and #VerveTherapeutics to reposition their ANGPTL3-targeting agents from currently only homoFH and potentially ASCVD...to much larger #MASH opportunity.

See also #EliLilly's solbinsiran and Arrowhead's zodasiran ANGPTL3 results:

Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study Discover why JACC is the ultimate publishing partner for your cardiovascular research.

Based on standard lipid-lowering therapy, ANGPTL-3 inhibition with SHR-1918 further reduces LDL-C by 21.7% to 29.9% in patients at moderate or higher risk of #ASCVD. These additional reductions are both dose and dosing-frequency-dependent. jacc.org/doi/10.1016/...

#JACC #ANGPTL3

CRISPR Therapeutics Provides First ANGPTL3 Data Good morning, biotech. Yesterday, regulatory uncertainty hit fever pitch with the appointment of Dr. Vinay Prasad to head the CBER divisio...

#CRISPR Therapeutics Provides First #ANGPTL3 Data (blog): rnaitherapeutics.blogspot.com/2025/05/cris... $CRSP $VERV

$CRSP out with #CTX310 #ANGPTL3 CRISPR in hypercholesterolemia/mixed dyslipidemia.

Highest dose (n=1) w/ substantial efficacy...but 0.8mg/kg 'lean body weight-based dose' sounds rather high for an LNP. Imp to learn more about liver tox, esp that n=1 subject.

www.globenewswire.com/news-release...

Zodasiran, an RNAi therapy, targets ANGPTL3, showing significant reductions in triglycerides and LDL in patients with mixed hyperlipidemia. A leap toward lower cardiovascular risk! #ANGPTL3 #RNAi #Hyperlipidemia PMID:38809174, N Engl J Med 2024